Abstract
In current studies we have aimed to establish 1) that Sandostatin® has a prolonged intravenous half-life in man; 2) that it causes suppression of growth hormone levels in acromegaly; 3) the dose necessary to achieve this suppression; 4) whether Sandostatin works in patients unresponsive to bromocriptine and whether there is any additive effect of using both drugs simultaneously; 5) whether there is nocturnal escape of growth hormone secretion on Sandostatin in comparison with bromocriptine and 6) the effects and side effects of long-term treatment, including an assessment of pituitary tumour size.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Wass, J.A.H., Davidson, K., Medbak, S., Besser, G.M. (1988). Somatostatin Octapeptide (SMS 201–995, Sandostatin®) in the Medical Treatment of Acromegaly. In: Lamberts, S.W.J. (eds) Sandostatin® in the Treatment of Acromegaly. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73694-0_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-73694-0_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73696-4
Online ISBN: 978-3-642-73694-0
eBook Packages: Springer Book Archive